자가 세포 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Autologous Cell Therapy Market size is expected to reach USD 45.36 Billion in 2034 from USD 7.31 Billion (2025) growing at a CAGR of 22.48% during 2026-2034.

The global autologous cell therapy market has gained significant attention as personalized medicine continues to advance. Autologous cell therapy involves using a patient's own cells for treatment, reducing the risk of immune rejection and improving treatment compatibility. This approach is increasingly used in regenerative medicine and certain cancer therapies.

Several factors are driving the growth of the autologous cell therapy market. Rising prevalence of chronic diseases and increasing interest in regenerative treatments have encouraged research and development in cell-based therapies. Additionally, advancements in biotechnology and cell processing technologies have improved the effectiveness of these therapies.

Looking ahead, the autologous cell therapy market is expected to grow as clinical research continues to expand. Improvements in cell isolation, processing, and storage techniques may enhance treatment outcomes. Furthermore, increasing investments in regenerative medicine and personalized healthcare will likely support long-term market development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• Stem Cell Therapies
• Non-Stem Cell Therapies

By Therapeutic Area

• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others

COMPANIES PROFILED

• Bluebird bio Inc, Novartis, Gilead Sciences Inc Kite, BristolMyers Squibb Company, Pharmicell Co Ltd, Johnson Johnson Janssen Global Services LLC, JW Therapeutics, Holostem Srl, Vertex Pharmaceuticals Inc, Autolus therapeutics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Stem Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Stem Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiovascular Disease (CVD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Musculoskeletal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapy Type
  • 6.2.2 By Therapeutic Area
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapy Type
  • 6.3.2 By Therapeutic Area
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapy Type
  • 6.4.2 By Therapeutic Area
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapy Type
  • 6.5.2 By Therapeutic Area
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapy Type
  • 6.6.2 By Therapeutic Area
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL AUTOLOGOUS CELL THERAPY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Bluebird Bio Inc
  • 8.2.2 Novartis
  • 8.2.3 Gilead Sciences Inc. (Kite)
  • 8.2.4 Bristol-Myers Squibb Company
  • 8.2.5 Pharmicell Co. Ltd
  • 8.2.6 Johnson & Johnson (Janssen Global Services LLC.)
  • 8.2.7 JW Therapeutics
  • 8.2.8 Holostem S.R.L
  • 8.2.9 Vertex Pharmaceuticals Inc
  • 8.2.10 Autolus Therapeutics